← Back to Search

HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer for Ovarian Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Jiangsu HengRui Medicine Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time of first dose of hrs-1167 or bevacizumab until the date of death (up to 24 months)
Awards & highlights

Summary

This study is a multicenter, open-label Phase Ib/II clinical trial to observe and evaluate the safety, tolerability and pharmacokinetics of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer mechanical characterization and preliminary evaluation of the efficacy of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer.

Eligible Conditions
  • Ovarian Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from time of first dose of hrs-1167 or bevacizumab until the date of death (up to 24 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from time of first dose of hrs-1167 or bevacizumab until the date of death (up to 24 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Disease Control Rate (DCR)
Duration of Response (DoR)
Objective Response Rate (ORR)
+3 more

Side effects data

From 2019 Phase 3 trial • 660 Patients • NCT01627249
18%
Vitreous floaters
17%
Vision blurred
13%
Conjunctival haemorrhage
12%
Eye pain
12%
Nasopharyngitis
11%
Hypertension
8%
Visual acuity reduced
7%
Headache
7%
Lacrimation increased
6%
Eye irritation
6%
Vitreous haemorrhage
6%
Dry eye
6%
Cataract
5%
Sinusitis
5%
Eye pruritus
2%
Renal failure chronic
2%
Renal failure
2%
Vomiting
1%
Osteomyelitis
1%
myocardial infarction
1%
coronary artery disease
1%
hypertensive heart disease
1%
Diabetic gastroparesis
1%
Cough
1%
Pneumonia
1%
Cellulitis
1%
Peripheral vascular disorder
1%
Diabetic ketoacidosis
1%
Dyspnoea
1%
Hypoglycaemia
1%
anaemia
1%
Chest pain
1%
Localised infection
1%
Sepsis
1%
Urinary tract infection
1%
Acute respiratory failure
100%
80%
60%
40%
20%
0%
Study treatment Arm
Aflibercept
Bevacizumab
Ranibizumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancerExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Jiangsu HengRui Medicine Co., Ltd.Lead Sponsor
643 Previous Clinical Trials
98,873 Total Patients Enrolled
7 Trials studying Ovarian Cancer
1,521 Patients Enrolled for Ovarian Cancer
~36 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top